·	Application No.	Applicant(s)
	10/013,071	ZHU ET AL.
Notice of Allowability	Examiner	Art Unit
	Robert B Mondesi	1653
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in to or other appropriate communication. This application is su	n the correspondence address this application. If not included nication will be mailed in due course. THIS
1. This communication is responsive to <u>October 29, 2004</u> .		
2. \boxtimes The allowed claim(s) is/are $\underline{1,3-12,15,17,18,21-23}$ and $\underline{95-9}$	<u>)7</u> .	
3. The drawings filed on are accepted by the Examiner	:	
 Acknowledgment is made of a claim for foreign priority un a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	been received. been received in Application	No
Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		reply complying with the requirements
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftsperson 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.1 each sheet. Replacement sheet(s) should be labeled as such in the 	on's Patent Drawing Review of Samendment / Comment or in 84(c)) should be written on the	n the Office action of edrawings in the front (not the back) of
7. DEPOSIT OF and/or INFORMATION about the depose attached Examiner's comment regarding REQUIREMENT F	it of BIOLOGICAL MATER OR THE DEPOSIT OF BIOL	RIAL must be submitted. Note the .OGICAL MATERIAL.
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Sun Paper No./M 8), 7. ☑ Examiner's Al	lail Date mendment/Comment tatement of Reasons for Allowance

Art Unit: 1653

DETAILED ACTION

Claims 1, 3-12, 15, 17, 18 and 21-23 are directed to an allowable product. Pursuant to the procedures set forth in the Official Gazette notice dated March 26, 1996 (1184 O.G. 86), claims 95-97, directed to the process of making or using the patentable product, previously withdrawn from consideration as a result of a restriction requirement, January 26, 2004 now subject to being rejoined. Process claims 95-97 hereby rejoined and fully examined for patentability under 37 CFR 1.104.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Dr. Palaiyur S. Kalyanaraman on November 18, 2004.

Please amend the following claims:

Claim 3 (presently amended) The compound according to claim [2] $\underline{1}$, wherein R^2 is H, U is N and P^4 is H.

Claim 96 (presently amended) A method of treating disorders associated with the "Hepatitis C Virus" HCV, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 1.

Art Unit: 1653

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert B Mondesi whose telephone number is 571-272-0956. The examiner can normally be reached on 9am-5pm, Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Robert B. Mondesi

ROBERT A:WAX
PRIMARY EXAMINER